2 Immunization and Respiratory Diseases

Attachment 4.

Immunization and Respiratory Diseases

FORM APPROVED

OMB No. 0920-0636

EXP DATE MM/DD/20YY

Public reporting burden of this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, GA 30333; ATTN: PRA (0920-0636).

Immunization and Respiratory Diseases

1. What is the general epidemiologic and demographic description of this emergency?

2. What is/are the major illness(s)/syndrome(s) or outcomes being reported and monitored during this emergency?

3. What is/are the suspected agent(s) thought to be associated with illness/syndrome(s) or outcomes during this emergency?

4. What is/are the suspected vehicle(s) or mode(s) of transmission thought to be associated with illness/syndrome(s) or outcomes during this emergency?

5. How many customers can your jurisdiction serve for dispensing critical treatment or prophylactic agent(s) in an hour?  6 hours?  12 hours?  24 hours? (Assuming the treatment or prophylactic agent(s) is/are fully available.)

6. What are the operational challenges (lack of public health/medical personnel, lack of general volunteers, lack of adequate facilities, etc.) that hinder your operations for delivery of critical treatment or prophylactic agent(s)?

7. How many (or what percentage) of your planned distribution or vaccination sites are up and operational?

8. What resource and/or personnel gaps are of concern to you (e.g. epidemiology services, laboratory assays, laboratory technicians, etc.)? What additional funds or resources are needed to addresses these gaps?

9. What challenges have you encountered in working with your local health departments and/or private providers to establish the capacity to monitor outbreaks of respiratory and/or vaccine-preventable diseases?

10. Please provide best practices related to your management of your most recent respiratory and/or vaccine-preventable disease outbreaks.